stockrow
Friday 6 November 2026
Export CGTX’s income statement to Excel — free account
Cognition Therapeutics, Inc.
CGTX Healthcare Biotechnology
- EPS
- +63.6%
- Free cash flow
- +45.4%
Quarter to June 2026, against a year earlier
0.69
0.05
+7.81%
Follow CGTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 4 | 4 | 4 | 0.0% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | (5) | (8) | (12) | (21) | (26) | (34) | (23) | (17) | +30.1% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (5) | (8) | (12) | (21) | (26) | (34) | (23) | (17) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.40) | (23.76) | (3.13) | (0.91) | (0.86) | (0.86) | (0.32) | (0.17) | (3.7%) | ||||||
| Cash flow | — | — | — | (0.14) | (6.76) | (0.70) | (0.78) | (0.53) | (0.72) | (0.34) | (0.20) | +15.7% | ||||||
| Capex | — | — | — | 0.00 | (0.02) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.14) | (6.78) | (0.70) | (0.79) | (0.54) | (0.72) | (0.34) | (0.20) | +15.6% | ||||||
| Book value | — | — | — | (2.66) | (25.22) | 9.88 | 1.70 | 0.82 | 0.47 | 0.47 | 0.36 | n/m | ||||||
| Shares, m | — | — | — | 22 | 1 | 5 | 24 | 30 | 40 | 73 | 83 | +22.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (3) | (3) | (4) | (19) | (16) | (28) | (25) | (18) | +41.2% | |||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | n/m | ||||||
| Free cash flow | — | — | — | (3) | (3) | (4) | (19) | (16) | (28) | (25) | (18) | +41.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 3 | 4 | 51 | 40 | 24 | 18 | 34 | 33 | +46.3% | |||||
| Net debt | — | — | — | 57 | 8 | (55) | (42) | (30) | (25) | (37) | (35) | n/m | ||||||
| Shareholders’ equity | — | — | — | (58) | (13) | 51 | 40 | 24 | 19 | 34 | 33 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (234.94) | (165.63) | (49.05) | (39.06) | (60.26) | (103.89) | (59.75) | (57.33) | +175.2 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 13.84 | 19.07 | 192.16 | (46.76) | (79.69) | (157.19) | (88.60) | (83.76) | (102.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 21 | 25 | 28 | 28 | 14 | — | (9.6%) | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 25 Oct 2026
Cognition Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NORD Nordicus Partners Corporation | $63.2M | — (loss-making) | — | −99.58% (below 0%: shrinking) | n/m | +62.18% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CING Cingulate Inc. | $61.7M | — (loss-making) | — | — | n/m | −24.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FBIO Fortress Biotech, Inc. | $61.4M | 0.6× | 0.8× | +14.04% (above 0%: growing) | n/m | −115.37% (below 0%: shrinking) | 67.18% | (53.46%) | Compare |
| TENX Tenax Therapeutics, Inc. | $61.0M | — (loss-making) | — | −77.98% (below 0%: shrinking) | n/m | −125.93% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CGTX Cognition Therapeutics, Inc. | $60.4M | — (loss-making) | — | — | n/m | +45.35% (above 0%: growing) | 0.00% | 0.00% | |
| SPRO Spero Therapeutics, Inc. | $59.4M | 7.4× | — (loss-making) | −95.61% (below 0%: shrinking) | n/m | +69.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CRDF Cardiff Oncology, Inc. | $58.8M | — (loss-making) | — (loss-making) | −14.05% (below 0%: shrinking) | n/m | −41.36% (below 0%: shrinking) | 100.00% | (9,245.19%) | Compare |
| GOSS Gossamer Bio, Inc. | $57.6M | — (loss-making) | — (loss-making) | −19.59% (below 0%: shrinking) | n/m | +16.32% (above 0%: growing) | 100.00% | (282.25%) | Compare |
| TELO Telomir Pharmaceuticals, Inc. | $57.5M | — (loss-making) | — | — | n/m | −45.34% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $60.2M | — | — | −48.78% | — | −32.82% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 27 April 2026
Ownership
Directors and executive officers, together
11.11%
Entities affiliated with BIOS Memory SPV I, LP
6.82%
Aaron Fletcher, Ph.D.
6.82%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement